You are browsing the global website, which contains information intended for residents outside of the United States of America (U.S.). This website is not country-specific and therefore may contain information that is not applicable to your country.
Rare Cells, with Single Cell Precision
We offer a menu of FDA-cleared and laboratory-developed tests (LDTs) used to detect and analyze circulating tumor cells in human blood with CELLSEARCH®. This minimally invasive liquid biopsy approach allows these tests to enable optimized patient care and comfort throughout the patient’s therapeutic journey.
Learn more about our Oncology portfolio
Learn more about our commitment in cell-based noninvasive prenatal testing (CB-NIPT)
Find out more about billing options
Learn more about setting up your account and ordering a test
If you already have an existing portal account, you can login here
Discover how our clinical lab service can support biopharma partners and clinical trials
Discover how our custom research lab service can support research projects
Single Cell Analysis
FFPE Analysis
View our complete list of Laboratory Developed Tests
Read the latest news from the Menarini Group
2022 - 10 - 13
These new codes are required to access Medicare/Medicaid insurance reimbursement for novel CELLSEARCH Circulating Multiple Myeloma Cell (CMMC) and HER2 Circulating Tumor Cell (CTC-HER2) assays, to monitor disease status in patients with life-threatening illnesses.
Huntingdon Valley, PA 13 October 2022-- Menarini Silicon Biosystems (MSB), Inc. is announcing that the AMA has issued Current Procedural Terminology (CPT®) Proprietary Laboratory Analyses (PLA) codes for two of its CELLSEARCH advanced liquid biopsy tests which received preliminary pricing determination by the US Centers for Medicare and Medicaid Services (CMS). Issuing of these codes represents a decisive step towards gaining broad access to Medicare/Medicaid reimbursement. This opens the door to affordable, less burdensome, minimally invasive liquid biopsy tests to improve the monitoring, and management of patients with challenging hematological and solid tumor types.
As part of the annual pricing process for CPT codes in the Medicare Clinical Laboratory Fee Schedule (CLFS), CMS recently issued a preliminary determination to price both CPT PLA codes on a ‘gapfill’ basis. Gapfilling occurs when no comparable, existing test is available and thereby recognizes the added value of MSB’s two assays. This gapfill process enables Medicare contractors to recommend CLFS pricing for each new CPT code in a vote to CMS the following year based on actual cost data provided by the testing laboratory/manufacturer instead of previously established payment rates. Final CLFS pricing for the CPT PLA codes would thus go into effect in January 2024. Further details on the CLFS pricing process are available on the CMS website.
The new CPT PLA codes include:
Both of these assays are laboratory developed tests (LDTs) regulated under Clinical Laboratory Improvement Amendments of 1988 (CLIA) regulations provided out of Menarini Silicon Biosystems’ clinical lab in Huntingdon Valley, PA.
The CELLSEARCH CMMC assay is intended for clinical use in patients with plasma cell disorders such as multiple myeloma (MM), the second most common blood cancer, as well as precursor conditions including monoclonal gammopathy of unknown significance (MGUS) and smoldering multiple myeloma (SMM). By capturing and enumerating CMMCs from peripheral blood, this assay has the potential to reduce invasive, often painful, and costly bone marrow (BM) biopsies to monitor MM disease progression and status in real-time.
The CELLSEARCH HER2 Circulating Tumor Cell (CTC-HER2) assay is intended to reduce the need for impractical or contraindicated tissue biopsy in patients with EpCAM (Epithelial Cell Adhesion Molecule)-expressing tumors that often overexpress the human epidermal growth factor receptor (HER) 2 biomarker. The HER family of receptors plays a central role in the pathogenesis of several human cancers and the introduction of HER2 directed therapies has the potential to dramatically influence the outcome of patients with HER2 positive breast and gastric/gastroesophageal cancers, making accurate testing for HER2 all the more critical.
According to Fabio Piazzalunga, President and CEO of Menarini Silicon Biosystems (MSB) Inc, “we are excited to be a step closer to making these tests more affordable and accessible for an increasing number of cancer patients who otherwise would not have the opportunity to benefit from the crucial clinical information and convenience of a minimally invasive liquid biopsy test. We are working hard to bring these innovative solutions to both healthcare providers and patients, knowing the considerable impact they can have on improving patient outcomes.”
CELLSEARCH CMMC and CELLSEARCH CTC-HER2 test results are available within 3 working days and allow treating physicians to timely access information for precision care.
About Menarini Silicon Biosystems Inc
MSB offers unique rare cell technologies and solutions that provide clinicians and clinical researchers with access to unparalleled data on rare cells and their molecular characterization.
In the US, MSB’s Pennsylvania-based lab is CAP/CLIA accredited, and ISO 15189-accredited for CELLSEARCH®. The MSB laboratory-developed tests (LDTs) are used to detect and analyze CTCs in human blood. The minimally invasive approach, on which they are based, allows them to contribute significantly to optimizing patient care and comfort throughout the patient’s therapeutic journey.
MSB Inc, based in Huntingdon Valley, PA., U.S., is a wholly owned subsidiary of the Menarini Group, a multinational pharmaceutical, biotechnology and diagnostics company headquartered in Florence, Italy, with more than 17,000 employees in 140 countries.
Footnotes/disclaimers
Read More
Login